Overview

  • Product nameAnti-Factor I antibody
    See all Factor I primary antibodies
  • Description
    Sheep polyclonal to Factor I
  • SpecificityThis product gives a single arc when tested by IEP against fresh human plasma. Identity has been confirmed by double diffusion (Ouchterlony) against human plasma and a known anti human Factor I.
  • Tested applicationsSuitable for: ELISA, ICC/IF, Other, Double Immunodiffusion, Immunoelectrophoresis, RIDmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Human Factor I purified from plasma.

  • Positive control
    • This antibody gave a positive result when used in the following formaldehyde fixed cell lines: HepG2
  • General notesThis antibody is also known as KAF/C3b Inactivator. The IgG concentration will range between 10-20 mg/ml.


    Factor I is a plasma protein of molecular weight 88 kDa, consisting of two disulphide linked chains of 50 and 38 kDa. Factor I is a serine protease with a high degree of specificity for C3b and C4b. It has a requirement for protein cofactors for cleavage of these complement proteins, Factor H, CR1 or MCP are required for C3b cleavage and C4bp or CR1 for C4b cleavage.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage bufferPreservative: 0.1% Sodium Azide
    Constituents: Glycine buffered saline, 0.1% EACA, 0.01% Benzamidine, 1mM EDTA, pH 7.4
  • Concentration information loading...
  • PurityIgG fraction
  • Purification notesAntiserum is prepared by immunisation of sheep with the human Factor I and, if necessary, adsorption to monospecificity by use of solid-phase adsorbents. An immunoglobulin fraction is then produced. The titre is adjusted so that inter-batch variation is within 10%. The product is finally 0.2µm filtered.
  • Primary antibody notesFactor I is a plasma protein of molecular weight 88 kDa, consisting of two disulphide linked chains of 50 and 38 kDa. Factor I is a serine protease with a high degree of specificity for C3b and C4b. It has a requirement for protein cofactors for cleavage of these complement proteins, Factor H, CR1 or MCP are required for C3b cleavage and C4bp or CR1 for C4b cleavage.
  • ClonalityPolyclonal
  • Myelomaunknown
  • IsotypeIgG
  • Light chain typeunknown
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab8843 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent concentration. PubMed: 20016463
ICC/IF 1/200.
Other Use at an assay dependent concentration.
Double Immunodiffusion Use at an assay dependent concentration. 10µL antiserum vs 10µL fresh plasma.
Immunoelectrophoresis Use at an assay dependent concentration. 100µL antiserum vs 10µL fresh plasma.
RID Use at an assay dependent concentration. 1.5µL antiserum/cm² gel vs 10µL fresh plasma.

Target

  • FunctionResponsible for cleaving the alpha-chains of C4b and C3b in the presence of the cofactors C4-binding protein and factor H respectively.
  • Tissue specificityPlasma.
  • Involvement in diseaseDefects in CFI are a cause of susceptibility to hemolytic uremic syndrome atypical type 3 (AHUS3) [MIM:612923]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
    Defects in CFI are the cause of complement factor I deficiency (CFI deficiency) [MIM:610984]. CFI deficiency is an autosomal recessive condition associated with a propensity to pyogenic infections.
  • Sequence similaritiesBelongs to the peptidase S1 family.
    Contains 1 Kazal-like domain.
    Contains 2 LDL-receptor class A domains.
    Contains 1 peptidase S1 domain.
    Contains 1 SRCR domain.
  • Cellular localizationSecreted > extracellular space.
  • Information by UniProt
  • Database links
  • Alternative names
    • AHUS3 antibody
    • ARMD13 antibody
    • C3b INA antibody
    • C3b inactivator antibody
    • C3B/C4B inactivator antibody
    • C3BINA antibody
    • CFAI_HUMAN antibody
    • Cfi antibody
    • Complement component I antibody
    • Complement control protein factor I antibody
    • Complement factor I antibody
    • Complement factor I heavy chain antibody
    • Complement factor I light chain antibody
    • F1 antibody
    • factor I antibody
    • FactorI antibody
    • FI antibody
    • I factor antibody
    • IF antibody
    • KAF antibody
    • Konglutinogen activating factor antibody
    • Light chain of factor I antibody
    • OTTHUMP00000219728 antibody
    • OTTHUMP00000221928 antibody
    see all

Anti-Factor I antibody images

  • ICC/IF image of ab8843 stained HepG2 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal donkey serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab8843 at 1/200 dilution overnight at +4°C. The secondary antibody (pseudo-colored green) was Alexa Fluor® 488 donkey anti- Sheep (ab150177) IgG used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (pseudo-colored red) at a 1/200 dilution for 1h at room temperature. DAPI was used to stain the cell nuclei (pseudo-colored blue) at a concentration of 1.43µM for 1hour at room temperature.

References for Anti-Factor I antibody (ab8843)

This product has been referenced in:
  • Lemaire M  et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45:531-6 (2013). Read more (PubMed: 23542698) »
  • Bienaime F  et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 77:339-49 (2010). ELISA . Read more (PubMed: 20016463) »

See all 2 Publications for this product

Product Wall

Thank you for your enquiry. The total protein concentration of the most recent lot is 14.2mg/mL. This antibody is IgG grade but is not preabsorbed. Specificity is checked by IEP against human plasma and identity confirmed by double diffusion ou...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"